← Companies
Company
Novartis
Company-level hearing-loss landscape profile across checked programs, evidence quality, modalities, indications, and open data checks.
Programs
2
linked to organization
Strong Evidence
0
1 status confirmed
Details Checked
2
0 open data checks
Company / Institution Links
2 / 0
industry vs non-industry records
Competitive Density
6
Pipeline Velocity
0
Completion Signal
0
Programs by Stage
Phase 1/21
Phase 21
Trial / Program Status
Completed2
Modality Mix
Gene Therapy1
Small Molecule1
Indication Coverage
Hearing Loss1
Sensorineural Hearing Loss1
Tinnitus1
Program Types
Therapeutic2
Population Tags
adult2
bilateral1
profound1
tinnitus1
Strong-Evidence Records
0 recordsNo strong-evidence records are linked to this organization yet.
Checked Records With Caveats
2 checked · 0 open checksCGF166 by Novartis
Status confirmed
Gene TherapyPhase 1/2Completed
Adenoviral ATOH1 gene transfer was intended to induce supporting cells to become new sensory hair cells in severe hearing loss.
Selurampanel (BGG492) by Novartis
Details checked
Small MoleculePhase 2Completed
Oral small-molecule AMPA/kainate receptor antagonist evaluated as BGG492/selurampanel for chronic subjective tinnitus.
Data checks: historical-completed-program, not-confirmed-current-active-development